Company intelligence / Profile preview

Mujisan Pharmaceuticals

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Mujisan Pharmaceuticals is a biotechnology company dedicated to developing next-generation small molecule pharmacological chaperones for the treatment of lysosomal storage disorders and neurodegenerative diseases. The company's primary focus is on GBA1-associated conditions, including Gaucher disease and GBA-related Parkinson's disease. By stabilizing the glucocerebrosidase enzyme, Mujisan's lead candidates aim to restore cellular function and mitigate the progression of these debilitating diseases. Based in San Francisco, the company is led by experienced pharmaceutical executives and is currently advancing its lead programs through pre-clinical development.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Mujisan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mujisan Pharmaceuticals.

Explore the full profile